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BaCKgRoUND aND aIMS: Mounting evidence supports 
an association between cholestatic liver disease and changes in 
the composition of the microbiome. Still, the role of the mi-
crobiome in the pathogenesis of this condition remains largely 
undefined.
appRoaCH aND ReSUltS: To address this, we have used 
two experimental models, administering alpha-naphtylisocyanate 
or feeding a 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine 
diet, to induce cholestatic liver disease in germ-free mice 
and germ-free mice conventionalized with the microbi-
ome from wild-type, specific pathogen-free animals. Next, 
we have inhibited macrophage activation by depleting these 
cells using clodronate liposomes and inhibiting the inflamma-
some with a specific inhibitor of NOD-, LRR-, and pyrin 
domain- containing protein 3. Our results demonstrate that 
cholestasis, the accumulation of bile acids in the liver, fails 
to promote liver injury in the absence of the microbiome 
in vivo. Additional in vitro studies supported that endotoxin 
sensitizes hepatocytes to bile-acid–induced cell death. We also 
demonstrate that during cholestasis, macrophages contribute to 
promoting intestinal permeability and to altered microbiome 
composition through activation of the inflammasome, overall 
leading to increased endotoxin flux into the cholestatic liver.
CoNClUSIoNS: We demonstrate that the intestinal mi-
crobiome contributes to cholestasis-mediated cell death 
and inflammation through mechanisms involving activa-
tion of the inflammasome in macrophages. (Hepatology 
2020;72:2090-2108).
The intestine is a selective barrier that pre-vents pathogenic bacteria translocating to the systemic circulation, while simultaneously 
allowing nutrient absorption. In the intestine, cross-
talk regulation among the microbiome, the immune 
system, and epithelial cells is essential to preserve 
barrier function.(1,2) Intestinal permeability is tightly 
regulated by the immune system as inflammatory 
cytokines (e.g., tumor necrosis factor [TNF] and 
interferon gamma) modulate the expression of tight 
junction (TJ) proteins.(3) In the intestine, the microbi-
ome shapes the immune system, rendering a tolerant 
environment where microbes and host cells can coex-
ist.(1,2) Reciprocally, inflammation can determine the 
composition of the intestinal microbiome,(4,5) adding 
another layer of complexity to the regulation of intes-
tinal permeability and barrier function.
The “leaky gut” hypothesis proposes that chronic 
liver disease is associated with breaching of the 
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intestinal barrier attributed to increased permea-
bility allowing bacterial translocation into the liver. 
There, microbe-derived products are recognized by 
the innate immune system through pathogen rec-
ognition receptors (Toll-like receptors and Nod-like 
receptors), leading to activation of the inflammasome 
and proinflammatory cytokine production.(6) When 
liver inflammation persists unresolved, the proin-
flammatory milieu has detrimental effects on paren-
chymal and nonparenchymal liver cells, leading to 
fibrosis and, ultimately, loss of function.(7,8)
Cholestasis occurs when the flow of bile from the 
liver to the small intestine is impaired, which is a com-
mon secondary pathological feature of chronic liver 
diseases.(9) In adults, the main etiologies of cholesta-
sis are primary biliary cholangitis (PBC) and primary 
sclerosing cholangitis (PSC), where tissue damage is 
typically linked to inflammation that triggers bile duct 
destruction and fibrosis.(10,11)
Recent studies have demonstrated that human 
cholestasis is associated with changes in microbiome 
composition. The microbiome in PSC patients (with 
or without inflammatory bowel disease [IBD]) is 
distinct from the microbiome of patients with IBD 
only; less diverse and enriched with Enterococcus 
and Lactobacillus in fecal samples(12-14) and enriched 
with Escherichia and Clostridiales species in muco-
sal samples.(15) Some of these changes observed in 
the microbiome of PSC patients also occur in PBC, 
including reduced diversity and increased abundance 
of Streptococcus and Lactobacillus species.(16)
In addition to changes in microbiome composition, 
increased permeability has been described in PBC 
patients,(17,18) and the close association of PSC with 
IBD(19) overall supports the hypothesis that translo-
cation of bacterial products from the leaky gut may 
relate to the pathogenesis of cholestatic disease.
Our work provides fundamental knowledge on the 
mechanisms mediating the pathogenesis of choles-
tatic liver disease. Our results demonstrate that the 
microbiome actively contributes to liver injury during 
cholestasis and provide mechanistic evidence on the 
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detrimental role of macrophages in contributing to 
cholestasis-mediated liver injury by promoting intes-
tinal permeability and altering the intestinal microbi-
ome composition.
Materials and Methods
eXpeRIMeNtal pRoCeDUReS IN 
aNIMalS
Germ-free (GF) mice were generated on a C57/
B6J background in the Disease Modelling Unit 
(University of East Anglia, UK). A subset of GF 
mice was conventionalized with the microbiome 
obtained from specific pathogen-free (SPF) wild-
type (WT) mice by administration of fecal matter 
by gavage 3 weeks before initiation of the experi-
ments (GF + WT).
Cholestasis was induced by administration of 
alpha-naphtylisocyanate (ANIT) for 48  hours and 
by feeding a subset of mice with a diet containing 
3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) for 
1 week as we described.(20) GF + WT mice were treated 
either with vehicle (corn oil) or ANIT (100  mg/kg) 
by oral gavage, whereas a subset of GF  +  WT mice 
were pretreated with clodronate (10 mL/kg) by intra-
peritoneal injection 24  hours before, at the time of 
the administration of ANIT, and 24 hours after. The 
NOD-, LRR-, and pyrin domain-containing protein 
3 (Nrlp3)-specific inhibitor, MCC950 (20 mg/kg), 
was administered to GF  +  WT mice in parallel to 
the administration of ANIT and 24 hours after. All 
ANIT-treated animals were euthanized 48 hours after 
gavage.
All experimental procedures were conducted in 
male mice from 8 to 12 weeks of age that were held 
in isolators in the germ-free facility at the Disease 
Modelling Unit (University of East Anglia, UK). All 
experiments were previously approved by the Animal 
Welfare and Ethical Review Body (University of East 
Anglia, Norwich, UK) and were performed following 
the guidelines of the National Academy of Sciences 
(National Institutes of Health publication 86-23, 
revised 1985) and were conducted within the provi-
sions of the Animals (Scientific Procedures) Act (1986) 
and the LASA Guiding Principles for Preparing for 
and Undertaking Aseptic Surgery (2010) under UK 
Home Office approval (70/8929).
StatIStICal aNalySIS
Data are expressed as mean ± standard error of 
the mean. Statistical significance was determined by 
two-way analysis of variance and by a Student’s t test 
when appropriate. 16s rRNA sequencing data analy-
sis was conducted with R statistical language Version 
3.00 (The R Foundation, https://www.r-proje ct.org/) 
as described in Hildebrand et al.,(21) employing the 
rtk software(22) or all data normalizations.
More information can be found in the Supplemental 
Material and Methods.
Results
tHe aBSeNCe oF tHe 
INteStINal MICRoBIoMe 
pRoteCtS tHe lIVeR FRoM 
INJURy aND INFlaMMatIoN 
DURINg CHoleStaSIS
We induced cholestasis in GF mice, lacking a 
microbiome, and in GF mice conventionalized 
with the microbiota obtained from SPF WT mice 
(GF  +  WT) using two experimental models; the 
administration of ANIT and feeding with a diet 
containing 0.1% DDC.
Sterile GF mice treated with ANIT for 48 hours 
showed low levels of liver-damage and cholestasis- 
serum markers and the virtual absence of necrotic areas 
in the liver (Fig. 1A,B). In contrast, conventionalized 
GF + WT showed severe liver injury after ANIT treat-
ment as evidenced by high levels of serum transami-
nases and alkaline phosphatase (AP) and wide areas of 
necrosis throughout the liver parenchyma (Fig. 1A,B)
The dramatic worsening of the liver phenotype in 
conventionalized GF  +  WT mice after ANIT treat-
ment was associated with increased inflammation, as 
shown by the significant increase of infiltrating mac-
rophages in the liver (Fig. 1C, D) and expression of 
proinflammatory cytokines (Fig. 1E) in conventional-
ized GF + WT mice compared to GF animals.
Macrophages represent the first line of defense 
against invading bacteria, promoting activation of 
the inflammasome, triggering the interleukin-1 
beta (IL1β)-dependent proinflammatory response 
by cleavage of pro-IL1β by caspase 1.(23,24) Our 
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results demonstrate that conventionalization with a 
WT microbiome promoted a mild activation of the 
inflammasome in vehicle/GF + WT mice, which was 
further exacerbated after ANIT treatment given that 
we found high levels of cleaved caspase 1 and cleaved 
IL1β in comparison to GF mice (Fig. 1F,G).
FIg. 1. Absence of a microbiome protects mice from cholestatic-induced liver injury and inflammation. (A) Levels of blood liver injury 
and cholestasis markers and (B) H&E staining of liver sections from GF and GF mice conventionalized with WT microbiome (GF + WT) 
treated with vehicle or ANIT (100 mg/kg) for 48 hours. (C) FC analysis on liver-isolated immune cells, (D) further quantification, and (E) 
qPCR analysis on liver extracts showing increased presence of macrophages and inflammation in ANIT/GF + WT mice. (F, G) Western 
blotting analysis of whole-liver lysates showing activation of the inflammasome. Images are representative of n ≥ 5 animals per treatment 
group. Values are mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 (GF vs. GF+WT). Abbreviations: ALT, alanine aminotransferase; AST, 
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FIg. 2. Absence of a microbiome protects mice from 0.1% DDC diet–induced liver injury and inflammation. (A) Levels of blood 
liver injury and cholestasis markers. (B) H&E staining of liver sections from GF and GF mice conventionalized with WT microbiome 
(GF + WT) fed with chow or 0.1% DDC diet for 1 week. (C) IHC using an anti-CK19 Ab in paraffin-embedded liver sections showing 
milder ductular reaction in GF mice compared to GF + WTs. (D) FC analysis on liver-isolated immune cells, (E) further quantification, 
and (F) qPCR analysis on liver extracts showing increased presence of macrophages and inflammation in 0.1% DDC/GF + WT mice. 
(G) Western blotting analysis of whole-liver lysates showing activation of the inflammasome. (H) Liver fibrosis was assessed by Sirius Red 
staining on liver sections. Images are representative of n ≥ 5 animals per treatment group. Values are mean ± SEM. *P < 0.05; **P < 0.01; 
***P < 0.001 (GF vs. GF + WT). Abbreviations: Ab, antibody; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FC, flow 
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Further experiments in mice fed with a 0.1% DDC 
diet for 1 week(20) confirmed the detrimental impact 
of the intestinal microbiome in the cholestatic liver. 
Sterile 0.1% DDC/GF mice showed significantly 
lower serum transaminases, but similar AP levels, 
compared to 0.1% DDC/GF  +  WT mice, which 
exhibited histological features characteristic of choles-
tatic disease including ductular reaction and areas of 
tissue damage (Fig. 2A,B). Immunohistochemical 
analysis confirmed significantly fewer cytokeratin 19 
(CK19)-positive cells in GF mice when compared to 
GF + WT mice after 0.1% DDC treatment (Fig. 2C 
and Supporting Fig. S1A).
The worsening on the liver phenotype in conven-
tionalized GF + WT mice after the 0.1% DDC diet was 
associated with increased inflammation, as evidenced 
by higher infiltration of macrophages (Fig. 2D,E), 
expression of proinflammatory markers (Fig 2F), and 
activation of the inflammasome (Fig. 2G) when com-
pared to GF mice.
GF mice had significantly reduced fibrosis when 
compared to conventionalized GF + WT mice, which 
showed higher collagen deposition in the liver after the 
0.1% DDC diet as evidenced by Sirius Red staining 
(Fig. 2H), and increased collagen and alpha-smooth 
muscle actin gene expression (Supporting Fig. S1B).
Overall, our results show that the microbiome 
exacerbates the progression of cholestatic liver disease.
CHoleStaSIS oCCURS 
INDepeNDeNtly oF tHe 
pReSeNCe oF tHe MICRoBIoMe 
tHat INFlUeNCeS tHe BIle 
aCID pool CoMpoSItIoN 
BeFoRe aND aFteR aNIt aND 
0.1% DDC tReatMeNt
The significant protection from cholestatic liver 
injury shown by mice lacking a microbiome could 
arguably reflect a lower degree of cholestasis, or result 
from a different bile acid metabolism and pool com-
position compared to GF  +  WT mice after ANIT 
and 0.1% DDC treatments.
Bile acid pool size was determined in liver, serum, 
and fecal samples using high-performance liquid 
chromatography (HPLC)/mass spectrometry (MS). 
In agreement with previous studies,(25) GF mice 
accumulated more bile acids in the liver while having 
secreted less in serum and feces at basal conditions 
(Fig. 3A; Supporting Tables S1-S3). After ANIT, 
GF and GF + WT mice showed elevated and com-
parable accumulation of bile acids in livers (Fig. 3A). 
Consistently with the induction of cholestasis, we 
found elevated presence of bile acids in serum in both 
groups that was significantly higher in ANIT/GF 
mice compared to ANIT/GF + WT animals, whereas 
fecal levels of bile acids were reduced and reached 
similar levels in both ANIT-treated groups (Fig. 3A).
Bile acid pool composition in livers after ANIT 
treatment was dominated by tauro beta (T-β-MCA) 
murocholic acid (MCA) similarly in both groups, with 
tauro alpha MCA and taurocholic acid (TCA) being 
predominant in GF + WT while β-MCA and tauro-
ursodeoxycholic acid were more abundant in GF mice 
(Supporting Table S1). In serum samples, secretion 
of TCA was comparable whereas ANIT/GF mice 
showed significantly more T-β-MCA and β-MCA 
than ANIT/GF  +  WT animals (Supporting Table 
S2). Fecal bile acids were predominantly T-β-MCA 
and TCA in ANIT/GF whereas ANIT/GF  +  WT 
mainly secreted cholic acid (CA) and deoxycholic acid 
(DCA) in agreement with the presence of a microbi-
ome (Supporting Table S3).
A comparable trend was found in livers, serum, and 
fecal samples after 0.1% DDC treatment (Fig. 3C), 
although the differences in bile acid composition were 
less pronounced between GF and GF  +  WT mice, 
with the exception of T-β-MCA, which was predomi-
nantly found in serum and feces from 0.1% DDC/GF 
mice (Supporting Tables S4-S6).
Analysis of the hepatic metabolism of xenobi-
otics and bile acids confirmed the expected down- 
regulation of the uptake transporter, organic anionic 
transporting polypeptide (Oatp), after ANIT(26) that 
was comparable in GF and GF + WT mice, whereas 
the reduction in Na+-taurocholate cotransporting 
polypeptide (Ntcp) expression was more pronounced 
in GF + WT animals (Fig. 3B). Canalicular export 
genes were similarly regulated in GF and GF + WT 
mice, and the mild differences in alternative trans-
porter expression did not reach statistical signifi-
cance (Fig. 3B). Phase I enzymes cytochrome P450, 
family 2, subfamily b, polypeptide 10 (Cyp2b10) 
and cytochrome P450, family 3, subfamily a, poly-
peptide 11 (Cyp3a11) were reduced whereas cyto-
chrome P450, family 2, subfamily c, polypeptide 70 
(Cyp2c70) was elevated in GF versus GF  +  WT 
mice at basal conditions. After ANIT treatment, all 
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were significantly decreased and reached comparable 
levels in ANIT/GF versus ANIT/GF  +  WT mice 
(Fig. 3B). Expression of glucuronidation-related 
enzyme UDP glucuronosyltransferase family 1 
member A1 (Ugt1a1) remained elevated in GF 
mice whereas it was mildly reduced in GF  +  WTs 
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(Fig. 3B). UDP glucuronosyltransferase family 
1 member A2 (Ugt1a2) was increased basally in 
GF  +  WT mice and was similarly reduced in both 
groups after ANIT (Fig. 3B). Last, glutathione 
S-transferase 3 (Gst3) expression was mildly higher 
in GF mice compared to GF + WT whereas no dif-
ferences were found in glutathione S-transferase 4 
(Gst4; data not shown) and glutathione peroxidase 
1 (Gxp1) after ANIT (Fig. 3B).
In 0.1% DDC–treated mice, we found decreased 
uptake (Oatp, Ntcp), as expected,(27) while Ntcp 
remained higher in GF compared to GF + WT mice 
(Fig. 3D). Increased basolateral (multidrug resis-
tance-associated protein 2 [Mrp2], multidrug resis-
tance-associated protein 4 [Mrp4]) and canalicular 
transport (bile salt export pump [Bsep] and mul-
tidrug resistance protein 2 [Mdr2]) were found in 
GF + WT mice compared to GF (Fig. 3D), though 
these changes did not prevent the increase in circu-
lating bile acids in 0.1% DDC/GF mice (Supporting 
Table S5). Phase I detoxification enzymes Cyp3a11 
and Cyp2c70 were elevated in GF  +  WT animals, 
and phase II and glutathione-metabolism–related 
genes were differentially regulated in both groups 
(Fig. 3D).
Although the microbiome influences bile acid 
hydroxylation and moderately impacts on bile acid 
transporter expression, overall, our results show that 
cholestasis, the accumulation of bile acids in the liver 
and serum, occurs independently of the presence of 
the intestinal microbiome.
BIle-aCID–INDUCeD Cell 
DeatH IS ReDUCeD IN 
HepatoCyteS FRoM geRM FRee 
MICe
To determine whether the liver protection observed 
in GF mice could result from the different bile acid 
pool composition (Supporting Tables S1-S6), we per-
formed in vitro studies where we exposed hepatocytes 
isolated from GF and conventionalized GF  +  WT 
mice to bile acids.
We confirmed that cultured GF and GF  +  WT 
hepatocytes retained a similar expression pattern of 
uptake, alternative, and canalicular transporters as 
well as a lower Cyp2b10 and Cyp3a11, with higher 
Cyp2c70 expression in GF hepatocytes (Fig. 4A). 
MS analysis showed that the conversion rate of che-
nodeoxycholic acid (CDCA) into MCA species was 
increased in GF hepatocytes whereas the conversion of 
DCA into CA was comparable in GF and GF + WT 
hepatocytes (Fig 4B). These results suggest that the 
hydroxylating capacity of GF hepatocytes could be 
mediated by Cyp2c70 and/or (the residual) Cyp2b10 
independently of Cyp3a11. This is in line with pre-
vious work showing that Cyp3a11 is dispensable for 
bile acid detoxification.(28)
We then determined the impact of different bile 
acids in hepatocyte viability and found lower caspase 
3 activity, indicative of cell death by apoptosis, in GF 
hepatocytes, as opposed to GF  +  WT hepatocytes, 
that showed profuse apoptotic cell death after CDCA, 
DCA, and glycocholic acid (GCA) and, to a lower 
degree, after TCA (Fig. 4C). Microscopic observa-
tion of cell cultures confirmed increased cell death in 
GF + WT mice compared to GF cells after bile acids 
(Supporting Fig. S2A).
Ultimately, to confirm our hypothesis that bacterial 
products contribute to bile-acid–mediated cell death, 
we pretreated GF hepatocytes with lipopolysaccha-
ride (LPS). This treatment significantly sensitized 
GF hepatocytes to bile-acid–induced cell death that 
evidenced a dramatic increase in caspase 3 activity, 
particularly in LPS/CDCA- and LPS/DCA-treated 
hepatocytes (Fig. 4D). The significant impact of bile 
acids in promoting cell death in LPS/GF hepatocytes 
occurred independently of the detoxification capacity 
of these cells. Thus, whereas LPS reduced the intracel-
lular presence of α-MCA (though not significantly), 
β-MCA and CA levels remained comparable to those 
found in GF mice (Supporting Fig. S2B).
FIg. 3. ANIT and 0.1% DDC promote similar cholestasis in GF and GF + WT mice while showing differences in bile acid metabolism. 
(A) Quantification of bile acid pool size in livers, serum, and fecal samples from WT and GF + WT mice by MS-HPLC at 48 hours 
after ANIT. (B) Gene expression determined by qPCR of xenobiotic and bile acids transporters, phase I and II detoxification, as well 
as glutathione metabolism in liver samples from GF and GF + WT mice after ANIT. (C) Quantification of bile acid pool size in livers, 
serum, and fecal samples from WT and GF + WT mice by MS-HPLC after feeding with 0.1% DDC for 1 week. (D) qPCR of xenobiotic 
and bile acids metabolism in liver samples from GF and GF + WT mice after 0.1% DDC. Graphs show results from n ≥ 5 animals 
per treatment group. Values are mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 (GF vs. GF + WT). Abbreviations: GSSH, oxidized 
glutathione; Mrp3, multidrug resistance-associated protein 3.
Hepatology, December 2020ISAACS-TEN, ECHEANDIA, ET AL.
2098
Overall, our in vitro results confirmed that expo-
sure to bacterial endotoxin sensitizes hepatocytes to 
bile-acid–induced cell death.
tHe INteStINal MICRoBIoMe 
CoNtRIBUteS to INCReaSe 
INteStINal peRMeaBIlIty 
aND INFlaMMatIoN DURINg 
CHoleStaSIS
Based on the leaky gut hypothesis, cholestasis 
is associated with increased intestinal permeability, 
allowing the translocation of bacterial products into 
the liver, where they contribute to injury and disease 
progression.
Our results demonstrate that cholestasis is suffi-
cient to moderately increase intestinal permeability 
in sterile mice given that ANIT/GF mice showed 
increased fluorescein isothiocyanate (FITC) pres-
ence in serum after oral administration (Fig. 5A). 
Also, conventionalization with a WT microbiome 
was sufficient to moderately increase intestinal per-
meability in vehicle/GF  +  WT mice, which was 
further exacerbated in response to ANIT-induced 
cholestasis, as evidenced by >10-fold increase in 
FITC presence in serum (Fig. 5A), supporting the 
implication of the microbiome in contributing to 
intestinal permeability.
We further assessed the intestinal permeability 
specifically in each part of the small intestine and 
colon. We found that expression of TJ proteins 
was primarily reduced in the colon from ANIT/
GF  +  WT mice, supporting that this area of the 
intestine is the most permeable during cholestasis 
(Fig. 5B). These results were confirmed by immuno-
fluorescence staining for occludin on intestinal sec-
tions that showed reduced apical membrane staining 
and cytoplasmic translocation in colonic enterocytes 
of ANIT/GF  +  WT mice compared to ANIT/GF 
(Fig. 5C).
FIg. 4. Endotoxin sensitizes GF hepatocytes to bile-acid–induced cell death. (A) qPCR to determine the expression of xenobiotic and 
bile acid transporters, phase I and phase II detoxification, as well as glutathione metabolism at basal conditions in cultured hepatocytes 
isolated from GF and GF + WT mice. (B) Quantification of α-MCA, β-MCA, and CA in the supernatants of cultured hepatocytes 
2 hours after CDCA (125 μM) and DCA (125 μM) stimulation. (C) Caspase 3 activity was determined in isolated hepatocytes from 
GF and GF + WT mice 2 hours after CDCA (125 μM), DCA (125 μM), GCA (250 μM), and TCA (500 μM) and in hepatocytes (D) 
pretreated for 4 hours with LPS (100 ng/mL). Values are mean ± SEM. In vitro experiments were done twice in triplicate. *P < 0.05; 
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In accordance with the increased intestinal per-
meability after ANIT treatment, we found elevated 
circulating LPS binding protein (LBP) in ANIT/
GF + WT mice serum samples compared to vehicle/
GF + WT animals (Supporting Fig. S3A).
Intestinal TJ protein expression is tightly regulated 
by inflammation.(29) Analysis of individual regions of 
the intestine in GF + WT mice after ANIT treatment 
showed low TNF and IL1β expression levels in the 
duodenum and jejunum that were mildly increased in 
the ileum and reached the highest concentrations in 
the colon (Fig. 5D, E). TNF and IL1β expression was 
moderately up-regulated in ANIT/GF mice, associ-
ated with a mild attenuation in TJ protein expression 
(Supporting Fig. S4A), suggesting regulatory crosstalk 
between bile acids and the immune system to pre-
serve intestinal barrier function independently of the 
microbiome.
These observations were confirmed in 0.1% DDC–
treated GF and GF + WT mice, which showed mildly 
decreased expression of TJ proteins and increased 
inflammation in the ileum, effects which were 
most pronounced in the colon of GF  +  WT mice 
(Supporting Fig. S5A-C).
Overall, our results support that cholestasis con-
tributes to increased intestinal inflammation and per-
meability that is further exacerbated in the presence of 
the microbiome.
aNIt-INDUCeD CHoleStaSIS 
pRoMoteS CHaNgeS IN tHe 
MICRoBIoMe CoMpoSItIoN oF 
gF + Wt MICe
Previous studies have shown that changes in the 
microbiome are associated with altered TJ protein 
expression.(30,31) We performed 16s ribosomal RNA 
(rRNA) sequence analysis of fecal samples with 
LotuS(32) and found significant taxonomical changes 
in the intestinal microbiome during ANIT-induced 
cholestasis in GF  +  WT mice, after correcting for 
absolute bacteria counts (Fig. 6A). Composition at 
genus level was significantly different in vehicle/
GF + WT compared to ANIT/GF + WT (P = 0.002 
per multivariate analysis of variance [MANOVA]; 
Fig. 6B,C). Univariate analysis showed an increased 
presence of Enterococcus, Lactobacillus, and Escherichia 
in ANIT/GF  +  WT when compared to vehicle/
GF  +  WT (Fig. 6C), in line with findings during 
cholestasis in PSC and PBC patients.(12-16)
Overall, our results show that the increased intes-
tinal permeability and inflammation observed during 
cholestasis correlated with changes in the microbiome 
composition.
MaCRopHage aCtIVatIoN By 
tHe INFlaMMaSoMe MeDIateS 
tHe DetRIMeNtal IMpaCt oF 
tHe INteStINal MICRoBIoMe 
IN CoNtRIBUtINg to 
CHoleStatIC-INDUCeD lIVeR 
INJURy
To determine the contribution of macrophages 
to liver injury during cholestasis in conventionalized 
(GF + WT) mice, we depleted macrophages with clo-
dronate-loaded liposomes. In parallel, to further dissect 
the mechanisms underlying macrophage activation 
during cholestasis, we inhibited the inflammasome 
using the inhibitor, MCC950, that specifically targets 
Nlrp3.(33)
Our results show that depletion of macrophages 
(Fig. 7A,B) correlated with a significant attenuation 
of inflammasome activation given that both cleaved 
caspase 1 and cleaved IL1β protein expression was 
practically undetectable in clodronate-treated con-
ventionalized GF + WT mice after ANIT (Fig. 7C). 
This finding was in line with the reduced inflam-
mation in ANIT/GF  +  WT mice after clodronate 
(Fig. 7D). Likewise, the specific inhibition of the 
inflammasome activation by Nrlp3 (Supporting 
Fig. S6A,B) also reduced the infiltration of 
FIg. 5. The intestinal microbiome exacerbates intestinal permeability during ANIT-induced cholestasis. (A) Quantification of circulating 
FITC in serum samples from GF and GF + WT mice after vehicle and ANIT (48 hours). (B) Western blotting analysis on intestinal 
protein extracts from duodenum, jejunum, ileum, and colon showing reduced expression of tight junctions in GF + WT mice particularly 
pronounced in the colon. (C) Immunofluorescence staining on intestinal sections supporting reduced apical occludin expression in ANIT/
GF + WT mice. (D) TNFα and (E) IL1β protein expression determined by ELISA on protein extracts isolated from duodenum, jejunum, 
ileum, and colon showing more pronounced inflammation in colons from ANIT/GF + WT mice. Values are mean ± SEM. *P < 0.05; 
**P < 0.01; ***P < 0.001 (vehicle/GF + WT vs. ANIT/GF + WT). Abbreviation: ELISA, enzyme-linked immunosorbent assay.
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macrophages in the liver and attenuated inflamma-
tion in MCC950-treated ANIT/GF  +  WT mice 
(Fig. 7A,B,D).
Ultimately, both the inhibition of macrophages 
and of Nrlp3 markedly attenuated liver injury in 
conventionalized GF  +  WT mice after ANIT treat-
ment, as evidenced by significant reduction of serum 
transaminases (Fig. 7E) and improved liver histology 
(Fig. 7F). The comparable AP levels in clodronate 
and MCC950/GF  +  WT mice (Fig. 7E) to those 
found in ANIT/GF  +  WT mice, together with the 
increased accumulation of bile acids in the liver and 
the comparable presence in serum and fecal samples 
(Supporting Fig. S7A-C; Supporting Tables S7-S9), 
supported that the protection exerted by macrophage/
inflammasome depletion was not resulting from a 
lower degree of cholestasis.
aCtIVatIoN oF MaCRopHageS 
By tHe INFlaMMaSoMe 
CoNtRIBUteS to INteStINal 
peRMeaBIlIty aND 
INFlUeNCeS tHe MICRoBIoMe 
CoMpoSItIoN DURINg 
CHoleStaSIS IN gF + Wt MICe
The protection observed in macrophage- and 
inflammasome-depleted mice could be a result of the 
reduced liver injury or of intestinal-dependent events, 
including a lower permeability that would limit the 
translocation of bacteria from a leaky intestine into 
the liver.
Accordingly, with the role of inflammation in con-
trolling TJ expression, we found a reduction of intes-
tinal permeability in clodronate/GF + WT mice and 
FIg. 6. Intestinal microbiome composition changes during ANIT-induced cholestasis. (A) Genus level PCoA (Bray-Curtis distance) 
after 16s rRNA sequencing of intestinal microbiome composition. (B) Composition plot of the 10 most abundant taxonomic groups at 
genus level. Note that because of the often-incomplete taxonomy, in some cases either the next known taxonomic level was chosen to 
represent the OTUs, whereas “Lachnospiraceae NK4A 136 group” does refer to a taxonomic group within family Lachnospiraceae. (C) 
Box plot of genera most significantly different between vehicle/GF + WT (n = 4) and ANIT/GF + WT (n = 8) mice. P value is shown 
above the plot; after multiple testing, all shown taxa were significantly different. *P < 0.05; **P < 0.01; ***P < 0.001 (vehicle/GF+WT vs. 
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FIg. 7. Depletion of macrophages and specific inhibition of Nrlp3 protects the liver from cholestasis-induced liver injury. (A) FC analysis 
on liver-isolated immune cells from GF, GF + WT, clodronate/GF+WT, and MCC950/GF + WT mice all treated with ANIT for 48 
hours to induce cholestasis and further (B) quantification showing reduced macrophage infiltration in clodronate- and MCC950-treated 
mice. (C) Western blotting analysis of whole-liver lysates showing whole and cleaved caspase 1 and whole and cleaved IL1B. (D) qPCR 
analysis on liver extracts showing decreased inflammation, (E) reduced transaminase levels, and AP and (F) improved liver parenchyma 
status in H&E staining. n = 4-8 animals per treatment group were analyzed. Values are mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 
(ANIT/GF + WT vs. clodronate/GF + WT and MCC950//GF + WT). Abbreviations: ALT, alanine aminotransferase; AST, aspartate 





















































































































Hepatology, Vol. 72, No. 6, 2020 ISAACS-TEN, ECHEANDIA, ET AL.
2103
FIg. 8. Macrophage depletion and inflammasome inhibition promote changes in the intestinal microbiome composition and reduce 
intestinal permeability during ANIT-induced cholestasis. (A) Quantification of circulating FITC in serum samples from GF + WT, 
clodronate/GF + WT, and MCC950/GF + WT mice after ANIT (48 hours). (B) Western blotting analysis on colon protein extracts 
showing increased expression of TJs associated with (C) reduced phosphorylation of AKT in clodronate/GF  +  WT and MCC950/
GF  +  WT mice. (D) Genus level PCoA (Bray-Curtis distance) after 16s rRNA sequencing of intestinal microbiome composition. 
(E) Composition plot of the 10 most abundant genera. (F) Box plot of genera most significantly different between ANIT/GF + WT 
(n = 8) and clodronate/GF+WT (n = 5) and MCC950/GF+WT (n = 4) mice. P value is shown above the plot, after multiple testing; all 
shown taxa were significantly different. n = 4-8 animals per treatment group were analyzed. Values are mean ± SEM. ***P < 0.001 (ANIT/
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MCC950/GF  +  WT mice during ANIT-induced 
cholestasis, evidenced by lower detection of FITC in 
the circulation (Fig. 8A). In addition, we found res-
toration of intestinal TJ in macrophage- and inflam-
masome-depleted GF  +  WT mice despite ANIT 
treatment, as shown by increased colonic occludin and 
E-cadherin protein expression (Fig. 8B). The marked 
reduction of intestinal permeability resulting from 
macrophage and inflammasome depletion was further 
supported by the lower circulating LBP in clodronate- 
and MCC950-ANIT/GF + WT mice when compared 
to ANIT/GF + WT animals (Supporting Fig. S8A).
Several mechanisms have been proposed to mediate 
the regulation of TJ by immune response, including 
activation of the phosphoinositide 3-kinase (PI3K)/
protein kinase B (AKT) pathway.(34,35) We found 
strong AKT phosphorylation in the colon of ANIT/
GF  +  WT mice whereas inhibition of macrophages 
and the inflammasome significantly attenuated AKT 
phosphorylation (Fig 8C), implicating this pathway 
in mediating the inflammation-TJ cross-regulation.
Analysis of the fecal taxonomic composition evi-
denced that inhibition of both the macrophages and 
of the inflammasome in ANIT-treated mice led to 
significant changes in microbiome diversity when 
compared to ANIT/GF + WT mice (P = 0.044 and 
P = 0.018 per MANOVA, respectively; Fig. 8D,E). 
No significant compositional differences were found 
between clodronate-ANIT/GF + WT and MCC950-
ANIT/GF + WT groups (P = 0.55), demonstrating 
that inhibition of the inflammasome had a compara-
ble effect to the depletion of macrophages on modu-
lating intestinal microbiome composition.
Further analysis of microbiome composition at 
the genus level showed that during ANIT-induced 
cholestasis, MCC950 treatment reduced the presence 
of Enterococcus and Parvibacter and increased the abun-
dance of uncultured Barnesiella sp. and Rikenellaceae 
RC9, as compared to ANIT/GF  +  WT samples 
(Fig. 8F). In clodronate-ANIT/GF  +  WT mice, we 
observed similar trends to MCC950-treated animals 
(Fig. 8F), in paired comparisons however, no signifi-
cance could be shown after multiple testing correction.
Overall, our results show that macrophages regulate 
intestinal permeability and microbiome composition 
during cholestasis through the inflammasome, and 
that this contributes to cholestatic disease progression 
by synergizing with bile acids to mediate hepatocellu-
lar injury in the liver (Table 1).
Discussion
In this study, we demonstrate that the intesti-
nal microbiome contributes to sensitize hepatocytes 
to bile-acid–induced cell death during cholestasis. 
In addition, we provide mechanistic evidence of the 
key role of activation of the inflammasome in mac-
rophages as a contributor of cholestatic liver injury 
by regulating intestinal permeability and intestinal 
microbiome composition.
Human cholestatic disease associates with changes 
in microbiome composition,(12-16) though whether the 
intestinal microbiome actively contributes to choles-
tatic disease or is a mere bystander of progression of 
the disease remains largely undefined.
The few mechanistic studies performed in mice 
investigating the contribution of the microbiome to 
the pathogenesis of cholestatic disease have provided 
conflicting results. Whereas some work supports the 
beneficial role of the microbiome in attenuating the 
progression of cholestasis and fibrosis,(36,37) recent 
studies suggest that the microbiome contributes to 
liver injury during cholestasis.(38,37) These controver-
sial findings support the need for further research to 
establish the role of the microbiome in the pathogen-
esis of human cholestatic disease.
Although murine experimental models may not 
fully recapitulate human disease, ANIT and feeding 
with 0.1% DDC are well-accepted models of scle-
rosing cholangitis relevant to PSC.(40,41) Moreover, 
the impact on intestinal permeability and micro-
biome composition observed in these preclini-
cal models support their suitability to unravel the 
mechanisms underpinning the pathogenesis in PSC 
and PBC.(12-18)
In our present study, we establish that intesti-
nal-derived endotoxin is required for the cytotoxic 
action of bile acids in hepatocytes, given that their 
accumulation in the liver cannot trigger liver injury 
per se in a sterile model system, specifically GF mice. 
Significant resistance of GF mice to cholestatic- 
induced liver injury could arguably result from the 
differential bile acid metabolism and/or pool compo-
sition (dominated by hydrophilic species), resulting 
from the lack of a microbiome. Analysis of xenobi-
otic and bile acid metabolism in the liver pointed to a 
decreased capacity to detoxify and export bile acids in 
GF mice. Nevertheless, this had no significant impact 
on the overall cholestasis after ANIT and 0.1% DDC 
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treatments, supporting that the protection observed in 
GF mice was not resulting from a different bile acid 
metabolism.
In GF mice, the bile acid pool is dominated by 
more hydrophilic, less toxic, species (Supporting 
Tables S1-S6). To rule out that the protection from 
cholestasis-mediated liver injury observed in sterile 
mice was attributed to different bile acid composition, 
we performed in vitro studies where we exposed pri-
mary hepatocytes isolated from GF and GF  +  WT 
to bile acids. We confirmed that, in our experimen-
tal setting, cultured hepatocytes retained key bile acid 
metabolic characteristics,(42) including the capacity to 
hydroxylate bile acids. Thus, whereas GF hepatocytes 
showed increased α/β-MCA levels when exposed to 
CDCA, the conversion of DCA into CA was compa-
rable in GF and GF + WT cells. Exposure to CDCA 
and DCA caused profuse caspase 3 activity and cell 
death in GF + WT hepatocytes compared to GF cells, 
suggesting that protection from bile-acid–induced cell 
death found in GF mice was not only resulting from 
the increased hydroxylation of CDCA into MCA 
species. Likewise, stimulation with GCA also caused 
significantly more cell death in GF + WT hepatocytes 
compared to GF cells whereas TCA had only a mild 
impact on cell death in cultures. Importantly, pretreat-
ing GF hepatocytes with LPS significantly increased 
bile-acid–mediated hepatocyte cell death, which 
seemed independent from the increased capacity of 
GF hepatocytes to hydroxylate CDCA into α-MCA.
Overall, our results support that endotoxin and bile 
acids act synergistically to promote hepatocellular cell 
death during cholestatic liver disease. Based on the 
known physiological low-grade leakage of bacterial 
taBle 1. the Intestinal Microbiome Contributes to liver Injury During Cholestasis by Increasing Intestinal permeability 
through Macrophage-Inflammasome activation
(A) GF mice present increased liver bile acids with no injury associated. (B) Conventionalization of GF mice leads to mild intestinal 
permeability. (C) Induction of cholestasis in GF mice leads to mild intestinal leakiness and inflammation that has no damaging impact 
on the liver, whereas (D) cholestasis in GF + WT mice caused significant intestinal permeability and inflammation and liver injury where 
endotoxin synergizes with bile acids to promote cell death. (E) Depletion of macrophages and Nrlp3 restores intestinal TJ protein expres-
sion and reduces liver injury associated with lower leakiness of intestinal endotoxin.
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products from the intestine,(43) it is tempting to spec-
ulate that this circulating endotoxin (pre)sensitizes 
hepatocytes to bile-acid–induced cell death when 
cholestasis occurs.
Intestinal permeability is regulated by TJ proteins, 
whose expression and cellular localization can be 
modulated by inflammation.(27) We therefore inves-
tigated whether macrophage-mediated inflammation 
may influence intestinal permeability in the context of 
cholestatic liver disease. Accordingly, we demonstrate 
that during cholestasis, elevated intestinal inflam-
mation associates with a reduction in TJ protein 
expression and increased permeability, particularly in 
the colon. Our further mechanistic studies showed 
that macrophages, through activation of the inflam-
masome, play a key role in the regulation of intestinal 
permeability, given that their depletion led to the res-
toration of TJ protein expression in the colon and the 
significant reduction in leakage of bacterial products 
into the circulation.
A recent study highlighted that administration of 
a pan-caspase inhibitor (inhibiting caspases 3, 6, and 
8) improved the liver phenotype in cholestatic mice 
by reducing intestinal permeability.(36) The role of 
intestinal Nrlp3 in mediating these effects was pro-
posed in that study, although the impact of the spe-
cific inhibition of Nrlp3 was not tested. Importantly, 
by using a specific inhibitor, we here provide evidence 
that Nrlp3 activation is key to the control of intes-
tinal permeability by controlling TJ protein expres-
sion. Our results suggest that activation of AKT may 
mediate the regulation of TJ expression by macro-
phages, supporting the previously described role of 
PI3K/ signaling in mediating the effects of TNF in 
down-regulating TJ expression described in human 
colonic monolayers.(32,33)
The role of the microbiome in educating the intesti-
nal immune system to generate a tolerant environment 
has been widely studied.(1) Likewise, the influence of 
the immune system in regulating intestinal defense 
against pathogens while remaining tolerant to the 
resident microbiome is established. Nonetheless, the 
specific mechanisms and signaling pathways involved 
in regulating the influence of the immune system in 
the intestinal microbiome composition remain largely 
undefined. There is evidence that during aging, 
increased intestinal permeability and systemic low-
grade inflammation (inflammaging) are associated 
with decreased microbial diversity.(4,44) However, aged 
TNF-knockout mice have comparable microbiome 
composition and intestinal barrier function to young 
mice,(4) supporting a causative relationship between 
TNF-driven inflammation, changes in the microbi-
ome, and intestinal permeability. In zebrafish, Early 
et al. showed that a specific subset of intestinal mac-
rophages is required to ensure the colonization of gut 
microbes and thus determine microbiome compo-
sition.(45) Our results show that modulating inflam-
mation by inhibition of macrophages/inflammasome 
affects microbiome composition during cholestasis, 
which may further contribute to promote intestinal 
permeability, thus aggravating cholestatic liver disease 
by allowing the translocation of bacterial products. 
Our observations in GF mice show that colonization 
with a WT microbiome leads to a moderate reduc-
tion in TJ expression, supporting the influence of the 
microbiome in regulating intestinal permeability. Our 
results are in agreement with previous studies where 
administration of (low doses of ) bacterial LPS(46) or 
presence of pathogenic bacteria (Escherichia coli)(47) led 
to the disruption of TJ, possibly mediated by inflam-
mation (TNF).
Our results also show that cholestasis induced 
an increase in inflammation independently of the 
presence of the microbiome in ANIT/GF mice that 
correlated with mild attenuation of the expression of 
TJ in the colon. These results point to a role of bile 
acids in preserving intestinal immune cell homeo-
stasis and barrier integrity during health. Thus, 
the absence of bile acids in the intestine during 
cholestasis may modulate intestinal immune cell 
activation and hence increase permeability at early 
stages of the disease, allowing the translocation of 
bacteria (and their products) into the liver, initiat-
ing injury in synergy with bile acids. The persistent 
decrease of bile acid flux into the intestine at later 
stages may lead to profound changes in microbiome 
composition and to increased inflammation, which 
may further contribute to reducing TJ expression 
and increasing intestinal permeability.
Our present work points to preserving intestinal 
barrier function, by mechanisms including the regula-
tion of (1) intestinal macrophages through the inflam-
masome and (2) the composition of the microbiome, 
as therapeutic approaches to treat cholestatic liver 
disease. To define the functionality of the microbi-
ome associated with liver disease and to better under-
stand how this influences intestinal inflammation and 
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barrier function will be essential to develop microbial 
therapeutics to treat or prevent cholestatic disease. 
There is increasing evidence of the efficacy of chang-
ing microbiome composition by the supplementa-
tion of liver bacteria and/or prebiotics on preserving 
intestinal barrier integrity and reducing liver injury 
in the context of alcoholic and nonalcoholic steato-
hepatitis.(48,49) Thus, future studies will determine the 
impact of interventions aimed at changing micro-
biome composition during cholestatic liver disease 
progression.
In summary, we here provide insights into the 
synergistic effects of bile acids and bacterial (compo-
nents) in triggering hepatocellular cell death in the 
context of cholestasis. Also, we propose that activation 
of intestinal macrophages, through the inflammasome, 
promotes intestinal permeability and influences micro-
biome composition, permitting the leakage of bacterial 
products to the liver where they contribute to hepa-
tocellular cell death. Overall, our study points to the 
regulation of intestinal macrophage/ inflammasome-
microbiome axis as a potential target for therapeutics 
to treat this condition.
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